Dr Lisa Crawford: The research matters because today’s treatment for myeloma might not be as effective tomorrow – Belfast Telegraph

Fundraising will support the work of leading local researcher in myeloma, Dr Lisa Crawford, who is a lecturer based at the Centre for Cancer Research and Cell Biology at Queens University Belfast.

r Crawford is pioneering new research into enhancing treatments for myeloma and to fund it Leukaemia and Lymphoma NI has launched the MyMATTERS (Myeloma Metabolic Manipulation To Enhance Response) appeal to raise the 100,000 needed. The charity strongly believes in prioritising research that will support the future needs which an increasing older population will require. It is estimated that by 2039, the population aged 65 and over will have increased by 74% and the population aged 85 and over will have increased by 157%.

The research aims to study metabolism within myeloma cells to identify ways to improve existing treatments making them last longer as well as improving the quality of life for thousands of people living with myeloma today and tomorrow.

With over 10 years experience in researching myeloma, Dr Crawford and her team aim to understand how metabolism works to help myeloma cells survive and from this research it will help identify ways to enhance existing treatments.

Dr Crawford feels passionately about finding answers to questions that could make such a huge difference for our loved ones, in Northern Ireland and across the world.

Speaking about the urgency of the research, she says: Myeloma may be more treatable, but it is still incurable. My research matters because todays treatment for myeloma might not be as effective tomorrow. This research is vital as existing treatments for myeloma are initially successful in treating the disease but patients often develop resistance and stop responding to treatment.

No two patients are the same and a one size fits all approach to treatment will not work.

New therapeutic strategies to tackle drug resistance and disease relapse are urgently needed for the growing elderly population that will develop myeloma over the next 10 years. More effective treatments will increase quality of life, adding life to years as well as years to life.

Experts indicate that myeloma is projected to rise by 11% in the UK by 2035.

New, enhanced and effective treatments will increase survival rates as well as improve the quality of care for the ageing population.

This is incredibly important as the Northern Ireland ageing population is set to increase and myeloma is a type of blood cancer normally prevalent in people over the age of 60.

Investing over 650,000 this year in local cancer research, Leukaemia and Lymphoma NI is the only charity in Northern Ireland solely dedicated to fighting leukaemia, lymphoma, myeloma and other related conditions.

To help fund MyMATTERS and world class life-enhancing research in Belfast, local people, communities and businesses are urged to get involved.

For more information on how you can help support MyMATTERS, visit llni.co.uk

Continue reading here:
Dr Lisa Crawford: The research matters because today's treatment for myeloma might not be as effective tomorrow - Belfast Telegraph

AXT adds new range of microscopes suited to in situ incubator applications – News-Medical.net

Mar 3 2020

AXT Pty Ltd is pleased to add the Etaluma range of Lumascopes to their life science portfolio. These compact high-resolution inverted microscopes provide live cell imaging capabilities and have been designed to operate inside standard CO2 incubators.

The Etaluma LS720 Lumascope for live cell imaging within an incubator.

The Lumascope range of microscopes is designed specifically for the examination and analysis of live cell morphology, viability and growth. Etaluma has designed the Lumascope from the ground up. By starting with the application, they are able to avoid redundant features seen in traditional inverted microscopes and instead focus on a custom design for a specific need.

Etalumas range of microscopes represents a new concept in digital fluorescence microscopy, which forms the backbone of life science imaging. Capable of produce high-quality multichannel images of both fixed and live samples, they feature zero pixel shift filters, high-resolution camera sensors and modern LED light sources.

With manual or automated options, they accommodate microplates, flasks, dishes, custom labware as well as slides which can be examined in situ inside incubators, biological safety cabinets and other environmentally controlled workstations.

Chris Shumate, CEO of Etaluma said:

We are excited to be working with the AXT team who have an excellent reputation and footprint in the life science microscopy market. We have every confidence that they will grow our market share in Australia and New Zealand."

Etaluma's range of microscopes will make an excellent addition to our product range and support our strategy to bring technologies that enable better live cell imaging to market. Their products are unrivalled on a cost to performance basis. We look forward to showing the capabilities of the Lumascopes to our customers."

Richard Trett, AXTs Managing Director

Etalumas range of live cell imaging microscopes will complement AXTs existing range of cell biology solutions.

Excerpt from:
AXT adds new range of microscopes suited to in situ incubator applications - News-Medical.net

Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook – Yahoo Finance

Reported Initial Clinical Data from FT500 Phase 1 Study in Advanced Solid Tumors, Supporting Safety and Tolerability of Multi-dose Treatment Paradigm for Off-the-shelf, iPSC-derived NK Cells

First Patients Treated with FT516, the First-ever Engineered iPSC-derived Cellular Immunotherapy, for AML and for B-cell Lymphoma in Combination with Rituximab

Initiated Enrollment of First-in-human Clinical Trial of FT596, the First-ever Cellular Immunotherapy Engineered with Three Active Anti-tumor Modalities

Ended Quarter with $261 Million in Cash, Cash Equivalents and Marketable Securities

SAN DIEGO, March 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the fourth quarter ended December 31, 2019.

In 2019, we made tremendous progress in pioneering the clinical development of off-the-shelf, iPSC-derived cancer immunotherapy. Our FT500 program demonstrated that multiple doses of iPSC-derived NK cells can be delivered off-the-shelf to a patient in a safe manner without patient matching. Additionally, our FT516 program provided initial clinical evidence that engineered iPSC-derived NK cells may confer anti-tumor activity and deliver clinically meaningful benefit to patients. We also showed the unmatched scalability of our proprietary iPSC product platform, having manufactured hundreds of cryopreserved, infusion-ready doses of our iPSC-derived NK cell product candidates at a low cost per dose in our new GMP manufacturing facility, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. In 2020, we look forward to additional clinical data from our FT500 and FT516 programs, and initial clinical data from FT596, our ground-breaking iPSC-derived CAR NK cell product candidate for the treatment of B-cell malignancies designed to overcome many of the limitations inherent in current CAR T-cell immunotherapies. We also expect to begin clinical investigation of our off-the-shelf, iPSC-derived NK cell programs in multiple myeloma with planned IND submissions for FT538, the first-ever CRISPR-edited, iPSC-derived cell therapy, and for FT576, our multi-antigen targeted, CAR-BCMA product candidate. Finally, under our collaboration with Memorial Sloan Kettering, we strive to be the first group in the world to bring off-the-shelf, iPSC-derived CAR T-cell therapy to patients.

Clinical Programs

Preclinical Pipeline

Fourth Quarter 2019 Financial Results

Today's Conference Call and Webcast

The Company will conduct a conference call today, Monday, March 2, 2020 at 5:00 p.m. ET to review financial and operating results for the quarter ended December 31, 2019. In order to participate in the conference call, please dial 877-303-6229 (domestic) or 631-291-4833 (international) and refer to conference ID 9879730. The live webcast can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at http://www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.

About Fate Therapeutics iPSC Product PlatformThe Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.

Story continues

About FT500

FT500 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line. The product candidate is being investigated in an open-label, multi-dose Phase 1 clinical trial for the treatment of advanced solid tumors (NCT03841110). The study is designed to assess the safety and tolerability of three once-weekly doses of FT500 as a monotherapy and in combination with one of three FDA-approved immune checkpoint inhibitor (ICI) therapies nivolumab, pembrolizumab or atezolizumab in patients that have failed prior ICI therapy. Despite the clinical benefit conferred by approved ICI therapy against a variety of tumor types, these therapies are not curative and, in most cases, patients either fail to respond or their disease progresses on these agents. One common mechanism of resistance to ICI therapy is associated with loss-of-function mutations in genes critical for antigen presentation. A potential strategy to overcome resistance is through the administration of allogeneic NK cells, which have the inherent capability to recognize and directly kill tumor cells with these mutations.

About FT516

FT516 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to express a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies. CD16 mediates antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. ADCC is dependent on NK cells maintaining stable and effective expression of CD16, which has been shown to undergo considerable down-regulation in cancer patients. In addition, CD16 occurs in two variants, 158V or 158F, that elicit high or low binding affinity, respectively, to the Fc domain of IgG1 antibodies. Numerous clinical studies with FDA-approved tumor-targeting antibodies, including rituximab, trastuzumab and cetuximab, have demonstrated that patients homozygous for the 158V variant, which is present in only about 15% of patients, have improved clinical outcomes. FT516 is being investigated in an open-label, multi-dose Phase 1 clinical trial as a monotherapy for the treatment of acute myeloid leukemia and in combination with CD20-directed monoclonal antibodies for the treatment of advanced B-cell lymphoma (NCT04023071). Additionally, the FDA has allowed investigation of FT516 in an open-label, multi-dose Phase 1 clinical trial in combination with monoclonal antibody therapy, including PDL1-, PD1-, EGFR- and HER2-targeting therapeutic antibodies, across a broad range of solid tumors.

About FT596FT596 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three anti-tumor functional modalities: a proprietary chimeric antigen receptor (CAR) optimized for NK cell biology, which contains a NKG2D transmembrane domain, a 2B4 co-stimulatory domain and a CD3-zeta signaling domain, that targets B-cell antigen CD19; a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies; and an IL-15 receptor fusion (IL-15RF) that promotes enhanced NK cell activity. In preclinical studies of FT596, the Company has demonstrated that dual activation of the CAR19 and hnCD16 targeting receptors, in combination with IL-15RF signaling, convey synergistic anti-tumor activity. Increased degranulation and cytokine release were observed upon dual receptor activation in lymphoma cancer cells as compared to activation of each receptor alone, indicating that multi-antigen engagement may elicit a deeper and more durable response. Additionally, in a humanized mouse model of lymphoma, FT596 in combination with the anti-CD20 monoclonal antibody rituximab showed enhanced killing of tumor cells in vivo as compared to rituximab alone. FT596 is being investigated in an open-label Phase 1 clinical trial as a monotherapy, and in combination with rituximab, for the treatment of advanced B-cell lymphoma and in combination with obinutuzumab for the treatment of chronic lymphocytic leukemia (NCT04245722).

About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Companys results of operations, financial condition and sufficiency of its cash and cash equivalents to fund its operations, as well as statements regarding the advancement of and plans related to its product candidates, clinical studies and preclinical research and development programs, the Companys progress, plans and timelines for the manufacture and clinical investigation of its product candidates, the timing for the Companys receipt of data from its clinical trials and preclinical studies, the Companys development and regulatory strategy, and the therapeutic and market potential of the Companys product candidates. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results observed in prior studies of the Companys product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Companys product candidates or in the initiation of, or enrollment of patients in, any clinical studies, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, difficulties or delays in patient enrollment in current and planned clinical trials, difficulties in manufacturing or supplying the Companys product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that the Companys expenditures may exceed current expectations for a variety of reasons. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Availability of Other Information about Fate Therapeutics, Inc.

Investors and others should note that the Company routinely communicates with investors and the public using its website (www.fatetherapeutics.com) and its investor relations website (ir.fatetherapeutics.com) including, without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites. The information posted on these websites could be deemed to be material information. As a result, investors, the media, and others interested in Fate Therapeutics are encouraged to review this information on a regular basis. The contents of the Companys website, or any other website that may be accessed from the Companys website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Condensed Consolidated Statements of Operations and Comprehensive Loss(in thousands, except share and per share data)(unaudited)

Condensed Consolidated Balance Sheets(in thousands)(unaudited)

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com

Link:
Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook - Yahoo Finance

Neuroscience: Overview, history, major branches

Neuroscientists focus on the brain and its impact on behavior and cognitive functions, or how people think.

They also investigate what happens to the nervous system when people have neurological, psychiatric, and neurodevelopmental disorders.

A neuroscientist can specialize in a wide range of fields, from neuroanatomy to neuropsychology. Research in this field can improve our understanding of both the brain and the body, how they work, and the health issues that affect them.

Neuroscience is an interdisciplinary science that works closely with other disciplines, such as mathematics, linguistics, engineering, computer science, chemistry, philosophy, psychology, and medicine.

Neuroscientists study the cellular, functional, behavioral, evolutionary, computational, molecular, cellular, and medical aspects of the nervous system. There are various fields that focus on different aspects, but they often overlap.

Researchers might look into brain activity in people with ailments such as Alzheimers disease. Tools used include MRI scans and computerized 3-D models. They may do experiments using cell and tissue samples.

The findings may lead to the development of new medications. Some neuroscientists are involved in treating patients.

Neuroscience affects many, if not all, human functions, but it also contributes to a better understanding of a wide range of common conditions.

These include:

A greater understanding of neurological factors can help in developing medications and other strategies to treat and prevent these and many other health issues.

The ancient Egyptians thought the seat of intelligence was in the heart. Because of this belief, during the mummification process, they would remove the brain but leave the heart in the body.

The ancient Greeks were among the first people to study the brain. They attempted to understand the role of the brain and how it worked and to explain neural disorders.

According to an article in Scientific American, Aristotle, the Greek philosopher, had a theory that the brain was a blood-cooling mechanism.

Pierre Paul Broca (1824-1880) was a French physician, surgeon, and anatomist. He worked with patients who had brain damage. He concluded that different regions in the brain were involved in specific functions.

The part of the brain known as Brocas area is responsible for some speech and other functions. Damage to this area during a stroke can lead to Brocas aphasia, when a person can no longer produce accurate or coherent speech.

In the 19th century, von Hemholtz, a German physician and physicist, measured the speed at which nerve cells produced electrical impulses.

During 1873, Gamillo Golgi, an Italian physician, pathologist, and scientist, used silver chromate salt to see what neurons looked like.

Early in the 20th century, Santiago Ramn y Cajal, a Spanish pathologist, histologist, and neuroscientist, hypothesized that the neurons are independent nerve cell units.

In 1906, Golgi and Cajal jointly received the Nobel Prize in Physiology or Medicine for their work and categorization of neurons in the brain.

Since the 1950s, research and practice in modern neurology have made great strides, leading to developments in the treatment of stroke, cardiovascular disease, multiple sclerosis (MS) and other conditions.

Scientific developments have enabled neuroscientists to study the nervous systems structure, functions, development, abnormalities, and ways it can be altered.

Some major branches of neuroscience can be broadly categorized in the following disciplines:

Affective neuroscience: Research looks at how neurons behave in relation to emotions.

Behavioral neuroscience: This is the study of how the brain affects behavior.

Clinical neuroscience: Medical specialists, such as neurologists and psychiatrists, look at the disorders of the nervous system from basic neuroscience findings to find ways to treat and prevent them. They also look for ways to rehabilitate those who have undergone neurological damage. Clinical neuroscientists consider mental illnesses as brain disorders.

Cognitive neuroscience: This looks at how the brain forms and controls thoughts, and the neural factors that underlie those processes. During research, scientists measure brain activity while people carry out tasks. This field combines neuroscience with the cognitive sciences of psychology and psychiatry.

Computational neuroscience: Scientists try to understand how brains compute. They use computers to simulate and model brain functions, and applying techniques from mathematics, physics, and other computational fields to study brain function.

Cultural neuroscience: This field looks at the interaction between cultural factors and are genomic, neural, and psychological processes. It is a new discipline that may help explain variations in health measures between different populations. Findings may also help scientists to avoid cultural bias when designing experiments.

Developmental neuroscience: This looks at how the brain and the nervous system grow and change, from conception through adulthood. Information gathered helps scientists understand more about how the neurological systems develop and evolve. It enables them to describe and understand a range of developmental disorders. It also offers clues about how and when neurological tissues regenerate.

Molecular and cellular neuroscience: Scientists look at the role of individual molecules, genes, and proteins in the functioning of nerves and the nervous system at a molecular and cellular level.

Neuroengineering: Researchers use engineering techniques to better understand, replace, repair, or improve neural systems.

Neuroimaging: This is a branch of medical imaging that concentrates on the brain. Neuroimaging is used to diagnose disease and assess the health of the brain. It can also be useful in the study of the brain, how it works, and how different activities affect the brain.

Neuroinformatics: This field involves collaboration between computer scientists and neuroscientists. Experts develop effective ways to collect, analyze, share, and publish data.

Neurolinguistics: Specialists investigate how the brain enables us to acquire, store, understand, and express language. It helps speech therapists develop strategies to help children with speech difficulties or people who wish to regain their speech after, for example, a stroke.

Neurophysiology: This looks at how the brain and its functions relate to different parts of the body, and the role of the nervous system, from the subcellular level to whole organs. It helps scientists understand how human thought works and provides insight into disorders relating to the nervous system.

Neuroscience is a new and important field with implications for every aspect of how people move, think, and behave. In 2007, it was estimated that abnormal neurological conditions were thought to affect up to 1 billion people worldwide.

People who join this profession need to have an interest in science and math. Most neuroscientists start out by completing a bachelors degree in neuroscience before then pursuing a PhD.

Those who wish to do clinical work and treat patients must also train first as a Medical Doctor (MD) and complete a medical residency. They must also pass the United States Medical Licensing Examination.

They may then take a postdoctoral fellowship, for example, in a lab, to get further training before applying for a job.

According to the United States Bureau of Labor Statistics, the median annual salary of a medical scientist, including neuroscientists, in 2016 was $80,530. Salaries ranged from a low of $57,000 to a high of $116,840.

Read the rest here:
Neuroscience: Overview, history, major branches

Immersion Neuroscience Reveals What Folks Really Love with a Little Help From PR Mavens at Bob Gold & Associates – Broadcasting & Cable

Immersion Neuroscience, the worlds most advanced predictive software company unlocking neuroscience to measure what people love, has selected Bob Gold & Associates, a nationally recognized boutique public relations and marketing agency, as its public relations agency of record to help launch its new cloud-based audience prediction platform. The Immersion platform helps companies identify, quantify and predict what live or taped events, training, and entertainment motivate audiences to action so that companies can significantly improve their ability to connect with consumers and increase ROI.

"With more than two decades of research, weve developed an entirely new way to understand how the brain values content, and how to predict what content will drive actions with high accuracy," said Paul J. Zak, Ph.D., Founder of Immersion. We coined the term immersion to denote a measurable neurologic state, and today, Immersion offers an easy to use and powerful tool that allows any company to analyze content and predict how audiences will respond. And it doesn't take a neuroscientist to know that Bob Gold & Associates, with their unparalleled expertise and a proven track record, is the right company to help get our story told.

Immersions proprietary solution and software is the world's most accurate way to measure the brain's unconscious emotional responses to virtually any type of content whether its video, music, live events, training, educational resources and more. Developed by distinguished research scientists, Immersions simple to use and scalable predictive SaaS platform democratizes neuroscience so that anyone can measure what people love at scale.

Life doesnt happen inside a lab, Zak added. Until now, companies could only measure what people in the real world said they liked not how their brains were truly valuing an experience. Immersion is able to measure what folks truly, viscerally love, anywhere, anytime and in real time.

The Immersion platform infers when the brain values an experience in real-time with a small wearable sensor that can be used anywhere. Unlike traditional neuroscience technologies that use expensive, immobile and delicate lab equipment and require highly trained professionals to collect and analyze the data, Immersion takes multiple measures of brain activity and puts them into an easy to understand 0-10 measure collected every second. Immersions clients use the platform anywhere, anytime and at scale, empowering companies to predict future behavior and market outcomes with 90% or better accuracy.

"Immersion is a revolutionary company. With their unique cloud-based solution, measuring brain activity is no longer confined to a laboratory with expensive instruments," said Bob Gold, CEO of Bob Gold & Associates. "There are billions of dollars being spent in original programming, half of which never connects with audiences. Today for every network and streaming service, hits are everything. Immersion has proven, with peer-reviewed publications and blinded studies, its ability to identify hit shows, movies, songs and so much more.

Because its built in the cloud, and not in a lab, Immersions software is portable and effortlessly scalable, enabling clients to leverage the power of neuroscience on the fly, anywhere in the world. And while other companies can take months to compile results, Immersions software provides an immediate assessment, unlocking the power of neuroscience for anyone without the need for extensive training.

In one study, for example, two measures from the platform peak immersion, and frustration were enough to predict the top-rated unscripted TV shows with 84% accuracy.

Many leading global brands are already utilizing Immersion in countless ways. This includes shaping content and business decisions by predicting hit TV shows and movies, chart-topping songs, sales bumps, TV ratings, viral content, what has the highest impact at live events, and even HR and corporate training, all by accurately identifying what is truly valued by audience members brains.

For more about Bob Gold & Associates, visit http://www.bobgoldpr.com.

To learn more about Immersion, visit http://www.getimmersion.com.

For more information, contact:

Bob Gold & Associates

310-320-2010

immersion@bobgoldpr.com

Original post:
Immersion Neuroscience Reveals What Folks Really Love with a Little Help From PR Mavens at Bob Gold & Associates - Broadcasting & Cable

Too Much Excitation: The Neural Basis of Sensory Hypersensitivity – Technology Networks

Many people with autism spectrum disorders are highly sensitive to light, noise, and other sensory input. A new study in mice reveals a neural circuit that appears to underlie this hypersensitivity, offering a possible strategy for developing new treatments.MIT and Brown University neuroscientists found that mice lacking a protein called Shank3, which has been previously linked with autism, were more sensitive to a touch on their whiskers than genetically normal mice. These Shank3-deficient mice also had overactive excitatory neurons in a region of the brain called the somatosensory cortex, which the researchers believe accounts for their over-reactivity.

There are currently no treatments for sensory hypersensitivity, but the researchers believe that uncovering the cellular basis of this sensitivity may help scientists to develop potential treatments.

We hope our studies can point us to the right direction for the next generation of treatment development, says Guoping Feng, the James W. and Patricia Poitras Professor of Neuroscience at MIT and a member of MITs McGovern Institute for Brain Research.

Feng and Christopher Moore, a professor of neuroscience at Brown University, are the senior authors of the paper. McGovern Institute research scientist Qian Chen and Brown postdoc Christopher Deister are the lead authors of the study.Too much excitationThe Shank3 protein is important for the function of synapses connections that allow neurons to communicate with each other. Feng has previously shown that mice lacking the Shank3 gene display many traits associated with autism, including avoidance of social interaction, and compulsive, repetitive behavior.

In the new study, Feng and his colleagues set out to study whether these mice also show sensory hypersensitivity. For mice, one of the most important sources of sensory input is the whiskers, which help them to navigate and to maintain their balance, among other functions.

The researchers developed a way to measure the mices sensitivity to slight deflections of their whiskers, and then trained the mutant Shank3 mice and normal (wild-type) mice to display behaviors that signaled when they felt a touch to their whiskers. They found that mice that were missing Shank3 accurately reported very slight deflections that were not noticed by the normal mice.

They are very sensitive to weak sensory input, which barely can be detected by wild-type mice, Feng says. That is a direct indication that they have sensory over-reactivity.

Once they had established that the mutant mice experienced sensory hypersensitivity, the researchers set out to analyze the underlying neural activity. To do that, they used an imaging technique that can measure calcium levels, which indicate neural activity, in specific cell types.

They found that when the mices whiskers were touched, excitatory neurons in the somatosensory cortex were overactive. This was somewhat surprising because when Shank3 is missing, synaptic activity should drop. That led the researchers to hypothesize that the root of the problem was low levels of Shank3 in the inhibitory neurons that normally turn down the activity of excitatory neurons. Under that hypothesis, diminishing those inhibitory neurons activity would allow excitatory neurons to go unchecked, leading to sensory hypersensitivity.

To test this idea, the researchers genetically engineered mice so that they could turn off Shank3 expression exclusively in inhibitory neurons of the somatosensory cortex. As they had suspected, they found that in these mice, excitatory neurons were overactive, even though those neurons had normal levels of Shank3.

If you only delete Shank3 in the inhibitory neurons in the somatosensory cortex, and the rest of the brain and the body is normal, you see a similar phenomenon where you have hyperactive excitatory neurons and increased sensory sensitivity in these mice, Feng says.Reversing hypersensitivityThe results suggest that reestablishing normal levels of neuron activity could reverse this kind of hypersensitivity, Feng says.

That gives us a cellular target for how in the future we could potentially modulate the inhibitory neuron activity level, which might be beneficial to correct this sensory abnormality, he says.

Many other studies in mice have linked defects in inhibitory neurons to neurological disorders, including Fragile X syndrome and Rett syndrome, as well as autism.

Our study is one of several that provide a direct and causative link between inhibitory defects and sensory abnormality, in this model at least, Feng says. It provides further evidence to support inhibitory neuron defects as one of the key mechanisms in models of autism spectrum disorders.

He now plans to study the timing of when these impairments arise during an animals development, which could help to guide the development of possible treatments. There are existing drugs that can turn down excitatory neurons, but these drugs have a sedative effect if used throughout the brain, so more targeted treatments could be a better option, Feng says.

We dont have a clear target yet, but we have a clear cellular phenomenon to help guide us, he says. We are still far away from developing a treatment, but were happy that we have identified defects that point in which direction we should go.ReferenceThijssen et al. (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimers disease and frontotemporal lobar degeneration. Nature Medicine. DOI: https://doi.org/10.1038/s41591-020-0762-2

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the article here:
Too Much Excitation: The Neural Basis of Sensory Hypersensitivity - Technology Networks

Duck flies to Capitol Hill as one of top undergrad researchers in U.S. – AroundtheO

Research matters, and scientists can do more to make their important work accessible to the public. Those are the messages UO biology major Rennie Kendrick takes to Congress this April.

The Stamps Scholar from Portland was chosen among 60 of the nations top undergraduate researchers to participate in Posters on the Hill, a Washington, D.C. event showcasing innovative student work and demonstrating the value of federal investments in undergraduate research.

Its exciting, said the Clark Honors College senior. It will be great for members of Congress to see whats happening at the undergraduate level. Its important to fund and encourage this research, because discoveries have been made by undergraduates important discoveries.

Sponsored by the Council on Undergraduate Research, the annual event highlights student research for members of Congress, congressional staffers and federal government officials. A national panel of experts in their respective fields selects the finalists, and Kendrick is the second UO student to attend since the university joined the council in 2014.

The Undergraduate Research Opportunity Program and Vice President for Research and Innovation are helping fund her trip.

Kendrick will be presenting a poster on memory and innovative thinking, the subject of her honors thesis. Her plans include meeting with members of Oregons congressional delegation. Assistant professor Dasa Zeithamova-Demircan is helping Kendrick with the project, part of their work in the UOs Brain and Memory Lab.

The research is novel and complex. But Kendrick is planning a straightforward presentation.

There seems to be a growing misunderstanding about science for the general public, as well as the politicians who make decisions and allocate resources, she said. As scientists, we need to be able to communicate.

Kendricks fascination with science started early. After learning about birds in the third grade, she wanted to be an ornithologist. For Christmas, shed ask for research-related gifts, such as her treasured weather measurement kit.

Kendrick first learned about neuroscience while preparing for the eighth-grade science fair. She started her project on memory the summer before school had even started, submitting her idea to the Institutional Review Board so she could conduct experiments with people.

When youre an eighth-grader, you cant do much with human subjects, she recalled. But I got my approval. And I checked out every neuroscience book they had at the library. I just could not get enough of it. I knew about psychology and biology, then they fused together in my mind. I realized there was an entire biology to how we memorize things and have memories. That blew my mind. From then on, I have wanted to be a neuroscientist.

Kendrick excelled at Portlands Grant High School, where she ran track and cross country, participated in the state championship cross country team, was part of the 2016 state girls 6A champion 4x400 meter relay squad and qualified for state in the 1,500- and 3,000-meter events. She also served as managing editor of Grant Magazine, participated in Grants award-winning Constitution Team which has competed in the We the People national finals sang in the Royal Blues chamber choir, and volunteered in a behavioral neuroscience lab at Oregon Health and Science University-Portland Veterans Affairs Medical Center, where she was a 2017 Portland Veterans Affairs research fellow.

She chose the UO because she was offered a Stamps Scholarship, the universitys most prestigious and generous scholarship. Granted by the UO and the Strive Foundation, it is awarded to just 10 incoming freshmen each year, five residents and five nonresidents.

Kendrick joined the UOs track and cross-country teams as a walk-on during her first year and continued until injuries ongoing stress fractures that sporadically kept her from competing forced her to step down this year.

Those were tough lessons, she said. You put so much time into something and tomorrow you could be on crutches. Thats a good analogy for research, because you can put years into a project and find that its a null result. You have to be OK with saddling up again and putting effort into something, even if you know it could all go wrong at the drop of a hat. Its a nonlinear progression sometimes, but you have to keep in mind you are still making progress.

Over the years, Kendrick has been able to participate in research opportunities and make the most of her undergraduate experience thanks to support from UO organizations such as the Undergraduate Research Opportunity Program, the Office of the Vice President for Research and Innovation, the Center for Undergraduate Research and Engagement and the Office of Distinguished Scholarships.

Kendrick and another student are collaborating with professor Alice Barkan on a genetics research project and Kendrick was a 2019 Peter ODay Research Fellow. She currently works in the UOs Brain and Memory Lab, as well as the McCormick Lab at the Institute of Neuroscience. She also teaches a supplemental instruction course for business calculus and tutors students in biology, math and chemistry.

After graduating this spring, Kendrick heads to the University of British Columbia, where shell be working in a lab studying mechanisms of fear memory formation. She hopes to someday join the faculty at a college or university, combining her top three interests: research, teaching and writing.

By Ed Dorsch, University Communications

View post:
Duck flies to Capitol Hill as one of top undergrad researchers in U.S. - AroundtheO

Vice Provost Nathan Urban to take position at Lehigh – University of Pittsburgh The Pitt News

Nathan Urban will leave his position as vice provost for Pitts graduate studies and strategic initiatives this summer to become the provost of Lehigh University.

According to a statement released by Provost and Senior Vice Chancellor Ann Cudd, details regarding the search for his successor will be announced in the coming weeks.

Urban started working in the Office of the Provost in 2015 as a vice provost for special projects and later became vice provost for graduate studies and strategic initiatives in 2017. He has also served as a professor and associate chair of the department of neurobiology, the associate director of the Brain Institute and co-director of the Center for the Neural Basis of Cognition.

During his time as vice provost for graduate studies and strategic initiatives, Urban established several programs in order to bring graduate students across the University closer together such as monthly newsletters, social media platforms, events and office hours. He also started the graduate studies retreat a daylong event that brings together administrators, faculty and students from 14 of Pitts graduate and professional schools. More recently, Urban served as a co-chair of the Plan for Pitt 2025 committee.

According to the statement, he is also regularly involved with the Postdoctoral Association and has assisted members in promoting resources from across the University to postdoctoral students.

Urban is also a Pitt alum and received a bachelors of science in neuroscience, math and philosophy and a Ph.D. in neuroscience from the University.

Urban worked for Carnegie Mellon from 2002 to 2015 before coming to Pitt. He began as a professor in the biological sciences department after completing a postdoctoral fellowship at the Max Planck Institute for Medical Research in Heidelberg, Germany. He later became the Frederick Schwertz Distinguished Professor of Life Sciences and head of the biological sciences department from 2010 to 2014. Urban served as CMUs interim provost from 2014 to 2015.

Read this article:
Vice Provost Nathan Urban to take position at Lehigh - University of Pittsburgh The Pitt News

The Hereditary Neuropathy Foundation’s Movement is Medicine Program Expands to Florida and Continues to Shed Light on the Impact Exercise Has on…

NEW YORK, March 3, 2020 /PRNewswire/ -- The Hereditary Neuropathy Foundation(HNF) Movement is Medicine is expanding across the US with its latest Summit announced for March 21, 2020 in Winter Park, Florida at the Center for Health and Wellbeing, which is a collaboration between the Winter Park Health Foundationand AdventHealth. The 80,000-square foot, state-of-the-art facility offers the best community health and wellness programs in Central Florida.

"The Neuromuscular Division of the AdventHealth Neuroscience Institute is overjoyed to partner with the Hereditary Neuropathy Foundation as a Center of Excellence. The HNF has established itself as an organization in which individuals with hereditary neuropathies-also known as CMT-come first. Our division echoes this goal of patients coming first. We are excited to host the Movement is Medicine program here in Orlando; this program will demonstrate not only how much exercise is necessary in hereditary neuropathies, but also how much fun exercise can be by forming new friendships and creating positive energy that can be healing in every way."

-Nivedita Jerath MD, MS Medical Director of Neuromuscular Medicine, AdventHealth

Sponsored by AdventHealth, this Movement is Medicine Summit will be free to attend and feature inspirational speakers, expert instructors and informational breakout sessions specifically curated by and for CMT patients.

Over 100 attendees are expected to participate, with children, caretakers and family members also welcome.

"HNF is thrilled to bring its groundbreaking Movement is Medicine program to Winter Park," said Allison Moore, Founder and CEO of HNF. "Our patient-centered approach to the treatment of CMT disease is aligned with the terrific work that Dr. Jerathand her team are doing at the AdventHealth Neuroscience Institute, and we couldn't be more excited to be holding our event at the Center for Health and Wellbeing.

Registerfor the Movement is Medicine Summit Orlando.

HNF is grateful for all who continue to help make these impactful Summits possible and who are making a difference in the lives of our courageous attendees.

The HNF team is also planning its annual 2-day Movement is Medicine Summit in Phoenix, AZ at Ability360 for November 13-14th, 2020.

About Hereditary Neuropathy Foundation (HNF)HNF, a non-profit 501(c) 3 organizationwhose mission is to increase awareness and accurate diagnosis of CMT and related inherited neuropathies, support patients and families with critical information to improve quality of life, and fund research that will lead to treatments and cures. HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD) program, a collaborative effort with academia, government and industry, to develop treatments for CMT. Currently, TRIAD involves many groups that span the drug discovery, drug development and diagnostics continuum.

About AdventHealth's Central Florida Division:Founded in 1908 by pioneering Seventh-day Adventists who believed in whole-person health healing the body, mind and spirit AdventHealth has grown into one of the largest nonprofit hospitals in the country, caring for more than two million patient visits per year in metro Orlando alone. AdventHealth operates more than 50 hospitals and hundreds of care centers in nearly a dozen states, making it one of the largest faith-based health-care systems in the United States.

Story continues

AdventHealth's Central Florida Division encompasses 20 hospitals in the seven counties in and surrounding metro Orlando: Orange, Seminole, Osceola, Polk, Lake, Volusia and Flagler. The Central Florida Division's care network also includes more than 30 Centra Care urgent-care centers; dozens of sports-rehab and imaging centers; and hundreds of physicians, ranging from primary care to a full spectrum of specialties.

AdventHealth Orlando, the division's flagship campus, serves both as a community hospital and as a major tertiary referral hospital for the region, much of the Southeast, the Caribbean and Latin America.

AdventHealth Orlando is a designated statutory teaching hospital and trains physicians from around the world on the newest technology and procedures. The system provides a wide range of health services, including many nationally and internationally recognized programs in cardiology, cancer, women's medicine, neuroscience, diabetes, orthopedics, pediatrics, transplant and advanced surgical programs.

The AdventHealth Research Institute has more than 250 investigators and more than 500 clinical trials in progress. AdventHealth Orlando is also home to the Translational Research Institute for Metabolism & Diabetes and the Nicholson Center for Surgical Advancement.

Contact: Allison MooreT: 1-855-HELPCMT (435-7268)E: allison@hnf-cure.org

(PRNewsfoto/Hereditary Neuropathy Foundation)

View original content to download multimedia:http://www.prnewswire.com/news-releases/the-hereditary-neuropathy-foundations-movement-is-medicine-program-expands-to-florida-and-continues-to-shed-light-on-the-impact-exercise-has-on-charcot-marie-tooth-cmt-301014819.html

SOURCE Hereditary Neuropathy Foundation

Excerpt from:
The Hereditary Neuropathy Foundation's Movement is Medicine Program Expands to Florida and Continues to Shed Light on the Impact Exercise Has on...

Nathan Urban announced as new provost – The Brown and White

Nathan Urban was announced as the new provost, as Pat Farrell steps down from the role in June, according to an email sent to the Lehigh community from President John Simon on March 2.

Urban will also assume the role of senior vice president for academic affairs. He is currently the vice provost of graduate studies and strategic initiatives at the University of Pittsburgh, according to the email.

Following a global search of candidates, Urban was selected as the ideal choice to help us continue our efforts to build a stronger university, Simon said in the email.

Simon said in the email Urban helped to improve communication between the students and the administration at the University of Pittsburgh, and he created a better graduate student experience and sense of community.

Urban is also associate chair of the department of neurobiology and professor at the University of Pittsburgh. He was previously head of the department of biological sciences from 2010-14 and interim provost from 2014-15 at Carnegie Mellon University.

With a Ph.D. in neuroscience and a B.S. in neuroscience, math and philosophy from the University of Pittsburgh, Urban earned his undergraduate degree in math and philosophy as a Rhodes Scholar at Oxford University. His work, which focuses on brain activity and analysis of behavior, has been published in scientific journals.

As provost, Urban will bring new ideas for ongoing initiatives like GO: The Campaign for Lehigh and the Path to Prominence. He will work with the rest of the administration to continue to make an impact in teaching, research and service, Simon said in the email.

Urban said in the university announcement he wants to be a part of Lehighs developing connection the the community and alumni, and he has a vision of continuing to improve the student experience while emphasizing a quality education and strong faculty.

Urban will replace Farrell on June 30.

More here:
Nathan Urban announced as new provost - The Brown and White